However, our clinically relevant preclinical PDTX mouse models confirm and support the conclusion that BRAF/MEK inhibitors combined with CDK4/6 inhibitors effectively inhibits tumor growth in BRAFV600E-mutant melanomas by simultaneous or subsequent targeting of the cell cycle machinery. Here, CDK4 is linked to melanoma.